Kv7 Related Drug Discovery Products
Membrane protein stable cell lines are widely used in many areas of biomedical research. Creative Biolabs can offer membrane protein stable cell lines to stablish in vitro models for High Throughput Screening.
Creative Biolabs offers high-quality, innovative tools to help research groups accelerate membrane protein drug discovery. They can be found by targets. If there is no product that meets your needs, please contact us.
Many voltage-gated K+ channels fall within one of the Kv subfamilies (Kv1.x to Kv12.x), which can be distinguished by sequence homology and the capacity to form heteromultimeric channels. The five members of the Kv7 family are known as Kv7.1 to Kv7.5 (or KCNQ1 to KCNQ5). The strong inhibitory K+ currents that these channels generate below the threshold potential are helpful in reducing or preventing unwanted membrane excitation. These channels are active at subthreshold membrane potentials. Neuronal Kv7 channels are found in the hippocampal and dorsal root ganglion neurons, as well as the peripheral nerves, throughout the central nervous system. Therefore, synthetic drugs that potentiate these channels can be used to treat conditions like epilepsy and neuropathic pain that involve neuronal hyperexcitability.
Creative Biolabs can offer high-quality Kv7 related tools to contribute to the success of drug discovery:
Overview of Kv7
Since muscarinic receptor activation potently inhibits low-threshold non-inactivating K+ channels generated by Kv7 subunits, they are also referred to as "M channels". Their biophysical characteristics make it possible to exert strong control over a neuron's firing rate, as do their unique protein subcellular distribution and biophysical characteristics. Five genes (KCNQ1 to KCNQ5) that encode the Kv7.1 to Kv7.5 pore-forming α-subunits have been discovered, and at least five genes (KCNE1 to KCNE5) that encode the KCNE1 to KCNE5 auxiliary β-subunits have also been discovered. The development of heteromultimeric channels from various pore-forming α-subunits and additional accessory β-subunits greatly increases the diversity of Kv7 currents. Cardiac IKs, a slowly activating portion of delayed rectifier K+ current, are mediated by the Kv7.1-KCNE heteromultimeric complex. The heteromultimeric channels produced by Kv7.2, Kv7.3, Kv7.4, and Kv7.5, and in particular Kv7.2-Kv7.3, appear to be the molecular correlates of M currents, according to a wealth of evidence. Epilepsy, arrhythmia, deafness, and neuromyotonia are examples of human illnesses resulting from hyperexcitability that have been linked to genetic abnormalities of Kv7 channels. Kv7 channels are crucial regulatory proteins for managing electrical excitability as a result.
Kv7 Drug Discovery
The prevalent occurrence of hyperexcitability is seen in a number of neurological disorders. A rise in inhibitory activity, such as K+ channel conductance, could offer a helpful counterforce and, as a result, therapeutic benefit, even if the reason of excessive membrane stimulation can vary. The importance of Kv7 channel openers for the treatment of many disorders should not be understated because Kv7 channels are present in a variety of tissues, including the heart, peripheral nerves, the central nervous system, and several non-excitable tissues. These channel activators are effective pharmaceutical tools for researching Kv7 function. More importantly, they have been shown to be effective in clinical studies as possible therapeutic agents for the management of mental and neurodegenerative illnesses, as well as epilepsy and other types of pain.
